Dr. Robert Ferris, MD

• Otolaryngology-Head and Neck Surgery

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Johns Hopkins School Of Medicine

  Medical School, 1995

• Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire, 2018-10-23

• EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment, 2022-06-20

• The cost of cure: Examining objective and subjective financial toxicity in head and neck cancer survivors, 2021-07-08

• B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma, 2021-06-07

• Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021, 2022-06-07

• Neuropilin-1 is a T cell memory checkpoint limiting long-term anti-tumor immunity, 2020-07-13

• Potential impact of the COVID-19 pandemic on financial toxicity in cancer survivors, 2020-04-28

• Surgical factors associated with patient-reported quality of life outcomes after free flap reconstruction of the oral cavity, 2021-10-26

• A Novel Surgeon Credentialing and Quality Assurance Process using Transoral Surgery for Oropharyngeal Cancer in ECOG-ACRIN Cancer Research Group Trial E3311, 2020-07-14

• Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology A Prospective Blinded Multicenter Study Performance of a Multigene Classifier in Thyroid Nodules With Indeterminate Cytology, 2018-11-08

• Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer, 2021-12-08

• Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding, 2020-07-17

• Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial, 2022-04-12

• Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer, 2020-06-11

• Phase I trial of cetuximab, radiation therapy, and ipilimumab in locally advanced head and neck cancer, 2022-04-01

• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC), 2019-07-15

• Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+T Cells, 2022-07-01

• Immunotherapy for head and neck cancer: Recent advances and future directions, 2019-11-01

• STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+status in head and neck cancer, 2018-02-20

• APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma, 2021-08-23

• The great debate at "Immunotherapy Bridge 2018”, Naples, November 29th, 2018, 2019-08-15

• Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI, 2020-06-02

• Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis, 2021-02-18